Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

PURPOSE: This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4). PATIENTS AND METHODS: Patients were randomly assigned 2:1 to receive 6-week cycles of enzastaurin 500 mg/d (1,125-mg loading dose, day 1) o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wick, Wolfgang, Puduvalli, Vinay K., Chamberlain, Marc C., van den Bent, Martin J., Carpentier, Antoine F., Cher, Lawrence M., Mason, Warren, Weller, Michael, Hong, Shengyan, Musib, Luna, Liepa, Astra M., Thornton, Donald E., Fine, Howard A.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2010
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2834468/
https://ncbi.nlm.nih.gov/pubmed/20124186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.2595
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars